清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Progressive myoclonic epilepsy as an adult-onset manifestation of Leigh syndrome due to m.14487T>C

医学 强直性脊柱炎 末端炎 妥珠单抗 内科学 百时美 物理疗法 阿达木单抗 胃肠病学 外科 关节炎 疾病 银屑病性关节炎
作者
Bart Dermaut,Sara Seneca,Lina Dom,Kaat Smets,Luc Ceulemans,Joél Smet,Boél De Paepe,Simon Tousseyn,Sarah Weckhuysen,Marc Gewillig,P. Pals,Paul M. Parizel,Jan De Bleecker,Paul Boon,Linda De Meırleır,Peter De Jonghe,Rudy Van Coster,Wim Van Paesschen,Patrick Santens
出处
期刊:Journal of Neurology, Neurosurgery, and Psychiatry [BMJ]
卷期号:81 (1): 90-93 被引量:33
标识
DOI:10.1136/jnnp.2008.157354
摘要

Background

Axial spondyloarthritis (axSpA) is characterized by inflammation of the spine. However, the disease can also be associated with extra-spinal manifestations such as inflammation of the entheses (enthesitis) and peripheral joints, which can add to the burden of disease. RAPID-axSpA (NCT01087762) is a Phase 3 clinical trial of certolizumab pegol (CZP) in patients (pts) with axSpA including pts with (ankylosing spondylitis [AS]) or without (non-radiographic axSpA [nr-axSpA]) radiographic damage of the sacroiliac joints.1

Objectives

To report the impact of CZP treatment on enthesitis (measured by Maastricht Ankylosing Spondylitis Enthesitis Score [MASES]) and peripheral joint swelling and tenderness.

Methods

The RAPID-axSpA trial was double-blind and placebo (PBO)-controlled to Week (Wk) 24. Pts fulfilled ASAS criteria and had active axSpA. Pts were originally randomized 1:1:1 to either CZP 200mg Q2W, 400mg Q4W (following 400mg loading dose at Wks 0, 2, 4) or PBO. Enthesitis (MASES; count of 0–13 affected sites), swollen joints (SJC; 0–66 joints) and tender joints (TJC; 0–68 joints) were assessed at baseline and at each study visit to Wk24. Data are presented here for the subsets of pts within the Full Analysis Set (FAS) with ≥1 swollen joint, ≥1 tender joint or ≥1 enthesial site affected at baseline. LOCF imputation was used for pts escaping to CZP, withdrawing or having missing measurements. No analyses of statistical significance were carried out on these data.

Results

At baseline, of the 324 pts in the FAS, 229 had enthesitis in ≥1 enthesial site, with a mean MASES score of 5.1; 123 had ≥1 swollen joint, with a mean SJC of 4.2; and 212 had ≥1 tender joint, with a mean TJC of 6.6. Improvements were seen in all three extra-spinal measures following CZP treatment. At Wk24 the mean change from baseline in MASES for CZP-treated pts was -2.9 compared to -0.9 for PBO pts; for SJC the mean change from baseline for CZP pts was -2.8 compared to -0.7 for PBO pts; and for TJC the mean change from baseline for CZP pts was -2.7 compared to -0.4 in PBO pts. Baseline severity of extra-spinal manifestations and improvements observed to Wk24 were similar between the AS and nr-axSpA subpopulations (Table). Improvements were also similar between both CZP dosing regimens (data not shown).

Conclusions

CZP treatment of axSpA patients was associated with a marked improvement in measures of enthesitis and extra-spinal joint inflammation. Similar improvements were seen in both the AS and nr-axSpA subpopulations.

References

Landewé R. Ann Rheum Dis 2014;73:39-47

Acknowledgements

The authors acknowledge Costello Medical Consulting for writing and editorial assistance which was funded by UCB Pharma.

Disclosure of Interest

P. Mease Grant/research support: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB Pharma, Vertex, Consultant for: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Celgene, Crescendo, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, UCB Pharma, Vertex, Speakers bureau: (Abbott) AbbVie, Amgen, BiogenIdec, BMS, Crescendo, Genentech, Janssen, Lilly, Pfizer, UCB Pharma, M. Dougados Grant/research support: UCB Pharma, Abbvie, Pfizer, Lilly, Novartis, Consultant for: UCB Pharma, Abbvie, Pfizer, Lilly, Novartis, O. Davies Shareholder of: UCB Pharma, Employee of: UCB Pharma, T. Nurminen Employee of: UCB Pharma, J. Sieper Consultant for: Abbott, Merck, Pfizer, UCB Pharma, Novartis, Lilly, Janssen, Speakers bureau: Abbott, Merck, Pfizer, UCB Pharma, Novartis, Lilly, Janssen

DOI

10.1136/annrheumdis-2014-eular.1558
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
鳗鱼飞松完成签到 ,获得积分20
1秒前
widesky777完成签到 ,获得积分0
11秒前
霜二完成签到 ,获得积分10
14秒前
xiaofeixia完成签到 ,获得积分10
56秒前
ys完成签到 ,获得积分10
1分钟前
grace完成签到,获得积分10
1分钟前
ll完成签到,获得积分20
1分钟前
852应助ll采纳,获得10
1分钟前
mojito完成签到 ,获得积分10
1分钟前
muriel完成签到,获得积分10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
奥利奥利奥完成签到 ,获得积分10
2分钟前
2分钟前
Dave发布了新的文献求助10
2分钟前
DouBo完成签到,获得积分10
3分钟前
Richardisme完成签到 ,获得积分10
3分钟前
qianchang完成签到,获得积分10
3分钟前
yuiop完成签到,获得积分10
3分钟前
liuyc完成签到 ,获得积分10
3分钟前
3分钟前
ll发布了新的文献求助10
3分钟前
糖果苏扬完成签到 ,获得积分10
3分钟前
科研通AI2S应助科研通管家采纳,获得10
3分钟前
zhang完成签到 ,获得积分10
4分钟前
蝴蝶完成签到 ,获得积分10
4分钟前
naczx完成签到,获得积分0
4分钟前
Dave发布了新的文献求助10
5分钟前
FashionBoy应助Dave采纳,获得10
5分钟前
yi完成签到,获得积分10
6分钟前
陈龙完成签到,获得积分10
6分钟前
rockyshi完成签到 ,获得积分10
6分钟前
刘刘完成签到 ,获得积分10
7分钟前
7分钟前
Dave发布了新的文献求助10
7分钟前
HCT完成签到,获得积分10
7分钟前
小象完成签到,获得积分10
7分钟前
7分钟前
在水一方应助Dave采纳,获得10
7分钟前
淡淡兔子完成签到 ,获得积分10
8分钟前
9分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990502
求助须知:如何正确求助?哪些是违规求助? 3532220
关于积分的说明 11256532
捐赠科研通 3271046
什么是DOI,文献DOI怎么找? 1805207
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234